Integrative epigenomic/genomic profiling and biomarker discovery in HPV+ and HPV-
Integrative epigenomic/genomic profiling and biomarker discovery in HPV+ and HPV-
批准号:
8193428
负责人:
LAURA ROZEK
金额:
$49.23万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-14 至 2016-07-31
关键词:
AccountingAutomobile DrivingBehaviorBenchmarkingBioinformaticsBiological MarkersCarcinogensCell LineCervical Squamous Cell CarcinomaClinicalClinical TrialsCommunitiesComplexDNA MethylationDNA Modification ProcessDataDevelopmentEmployee StrikesEpidemiological FactorsEpigenetic ProcessEtiologyExcisionGene ExpressionGenomeGenomicsGoalsHPV-High RiskHead and Neck CancerHead and Neck NeoplasmsHead and Neck Squamous Cell CarcinomaHead and neck structureHuman PapillomavirusIncidenceIndividualKnowledgeLifeLightLinkMalignant Epithelial CellMalignant NeoplasmsMethodsMichiganMolecularMolecular Epidemiology of CancerNational Center for Integrative Biomedical InformaticsNormal CellOralOropharyngealOropharyngeal Squamous Cell CarcinomaPathway interactionsPatientsPersonsPopulation SciencesPrimary NeoplasmRecurrenceResearchRiskRisk FactorsRoleSamplingSiteSmokerSmokingSpecialized Program of Research ExcellenceSpecimenSquamous cell carcinomaSurvival RateThe Cancer Genome AtlasTherapeuticTobaccoTobacco-Associated CarcinogenTranslational ResearchTumor Cell LineUniversitiesValidationadvanced diseasebasecarcinogenesischemical carcinogenesisclinically relevantepigenomicsexperiencefunctional genomicsgenome-widehigh throughput technologyhistone modificationimprovedinnovationkeratinocytemalignant oropharynx neoplasmmalignant tongue neoplasmmalignant tonsil neoplasmneoplastic cellnext generationnon-geneticnon-smokernoveloutcome forecastpatient populationprotein expressionresponsetooltranscriptomicstumor
中文摘要
描述(由申请人提供):很明显,hpv诱导的鳞状细胞癌(SCCs)和与烟草致癌物相关的鳞状细胞癌的分子机制存在差异。目前,头颈部鳞状细胞癌(HNSCC)的治疗不是基于HPV状态。扁桃体癌和舌癌的发病率每年都在增加,其中许多含有高风险的HPV。了解HPV(+)和HPV(-) HNSCC中不同的致癌因素对于制定个性化的治疗方法非常重要。要做到这一点,需要对HPV(+)和HPV(-) SCCs中驱动肿瘤行为和治疗反应的分子机制有更多的了解。我们的初步数据表明,HPV+和HPV-肿瘤之间存在显著的表观遗传差异,但要了解这些差异,必须考虑到基因表达和其他体细胞变化。我们建议使用基因表达、DNA甲基化和组蛋白修饰以及拷贝数变化来确定定义和区分hpv诱导和致癌物诱导的HNSCC的分子机制。本提案的总体目标是了解在考虑吸烟和其他流行病学因素的情况下,导致HPV(+)和HPV(-) HNSCCs致癌的异常分子途径的差异。我们的中心假设是,通过对HPV+和HPV-肿瘤细胞的基因组和表观基因组图谱使用先进的综合生物信息学方法,我们将能够将HPV+和HPV-肿瘤细分为高风险和低风险亚群。我们的长期目标是基于吸烟、分子因素和本研究确定的新靶点,准确预测和应用最适合个体HPV+和HPV- HNSCCs的治疗方案。在第一个目标中,将对来自HPV+吸烟者、HPV+非吸烟者和HPV-吸烟者以及相关正常细胞的HPV+和HPV-口咽细胞系和原发口腔/口咽(OPSCC)肿瘤进行全基因组分析,以定义和区分每种病因的异常分子途径。目标2将整合和表征基因组、表观基因组和相应的基因表达变化,通过开发、验证和应用综合方法来分析多方面的深度测序数据,从而根据临床相关性优先考虑结果。目标3将在更大的原发肿瘤样本样本中识别和验证最优先的发现。这将确认临床重要的生物标志物,并从临床标本中识别与病因、复发或肿瘤细胞存活相关的异常变化。我们从高通量技术到患者群体验证的分层方法以及创新的生物信息学方法将为理解和利用体细胞差异以实现最佳治疗应用铺平道路。总的来说,我们提出的研究将使我们更接近于OPSCCs的个性化治疗方案,并为研究界提供有价值的、可访问的工具,用于深度测序数据的综合分析和解释。
英文摘要
DESCRIPTION (provided by applicant): It is clear that differences exist between the molecular mechanisms in HPV-induced squamous cell carcinomas (SCCs) and those linked to tobacco carcinogens. Currently, treatment of head and neck SCC (HNSCC) is not based on HPV status. The incidence of tonsil and tongue cancers have been increasing annually and many contain high risk HPV. It is important to understand differing factors of carcinogenesis in HPV(+) and HPV(-) HNSCC to develop personalized treatment approaches. To do this requires more knowledge of the molecular mechanisms that drive tumor behavior and response to therapy in HPV(+) vs HPV(-) SCCs. Our preliminary data indicate that there are striking epigenetic differences between HPV+ and HPV- tumors, but to appreciate these differences, they must be considered in light of gene expression and other somatic changes. We propose to use gene expression, DNA methylation and histone modifications, and copy number changes to identify molecular mechanisms that define and differentiate HPV-induced from carcinogen-induced HNSCC. The overall objective of this proposal is to understand the differences in the aberrant molecular pathways leading to carcinogenesis in HPV(+) and HPV(-) HNSCCs taking into account smoking and additional epidemiological factors. Our central hypothesis is that by using advanced, integrative bioinformatics methods on the genomic and epigenomic profiles of HPV+ and HPV- tumor cells, we will be able to subdivide HPV+ and HPV- tumors into high and low risk subsets. Our long term goal is to accurately predict and apply the most appropriate treatment regimes for individual HPV+ and HPV- HNSCCs based on smoking, molecular factors and new targets identified in this study. In the first aim, whole-genome analyses will be performed on a well-characterized panel of HPV+ and HPV- oropharyngeal cell lines and primary oral/oropharyngeal (OPSCC) tumors from HPV+ smokers, HPV+ non-smokers, and HPV- ever smokers, and relevant normal cells to define and distinguish aberrant molecular pathways for each etiology. Aim 2 will integrate and characterize genomic, epigenomic and corresponding gene expression changes to prioritize results based on clinical relevancy by developing, validating, and applying integrative methods for the analysis of multifaceted deep sequencing data. Aim 3 will identify and validate top prioritized findings in a larger sample of primary tumor samples. This will confirm clinically important biomarkers and identify aberrant changes associated with etiology, recurrence, or survival in tumor cells from clinical specimens. Our tiered approach from high-throughput technologies to validation in a patient population together with innovative bioinformatics approaches will pave the way to understanding and exploiting somatic differences for optimal therapeutic application. Collectively, our proposed studies will bring us closer to personalized treatment regimes for OPSCCs, as well as provide valuable, accessible tools to the research community for integrative analysis and interpretation of deep sequencing data.
PUBLIC HEALTH RELEVANCE: Certain types of squamous cell carcinomas can be caused by the human papillomavirus (HPV), while others are not. In this proposal, we will study the non-genetic DNA modifications that modify protein expression and cellular behavior between HPV+ and HPV- cancers using advanced bioinformatics methods to understand the survival differences between these two types of tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Oral Dysplasias to Carcinomas: Multi-omics Study of Progression
-
批准号:10770832
-
项目类别:
-
资助金额:$70.66万
-
财政年份:2023
-
负责人:LAURA ROZEK
-
依托单位:
Downstream effects of HPV integration on survival/metastasis in oropharyngeal cancer
-
批准号:10260028
-
项目类别:
-
资助金额:$21.7万
-
财政年份:2020
-
负责人:LAURA ROZEK
-
依托单位:
Transcriptomic effects of curcumin and piperine in breast stem cells
-
批准号:8304701
-
项目类别:
-
资助金额:$7.78万
-
财政年份:2012
-
负责人:LAURA ROZEK
-
依托单位:
Transcriptomic effects of curcumin and piperine in breast stem cells
-
批准号:8465204
-
项目类别:
-
资助金额:$7.78万
-
财政年份:2012
-
负责人:LAURA ROZEK
-
依托单位:
Integrative epigenomic/genomic profiling and biomarker discovery in HPV+ and HPV-
-
批准号:8332792
-
项目类别:
-
资助金额:$47.68万
-
财政年份:2011
-
负责人:LAURA ROZEK
-
依托单位:
Integrative epigenomic/genomic profiling and biomarker discovery in HPV+ and HPV-
-
批准号:8911904
-
项目类别:
-
资助金额:$19.21万
-
财政年份:2011
-
负责人:LAURA ROZEK
-
依托单位:
Integrative epigenomic/genomic profiling and biomarker discovery in HPV+ and HPV-
-
批准号:8703636
-
项目类别:
-
资助金额:$41.1万
-
财政年份:2011
-
负责人:LAURA ROZEK
-
依托单位:
Integrative epigenomic/genomic profiling and biomarker discovery in HPV+ and HPV-
-
批准号:8508200
-
项目类别:
-
资助金额:$43.69万
-
财政年份:2011
-
负责人:LAURA ROZEK
-
依托单位:
Integrative epigenomic/genomic profiling and biomarker discovery in HPV+ and HPV-
-
批准号:9093942
-
项目类别:
-
资助金额:$18.55万
-
财政年份:2011
-
负责人:LAURA ROZEK
-
依托单位:
Methylation patterns in colorectal cancer
-
批准号:7282091
-
项目类别:
-
资助金额:$5.04万
-
财政年份:2005
-
负责人:LAURA ROZEK
-
依托单位:
Methylation patterns in colorectal cancer
-
批准号:7124718
-
项目类别:
-
资助金额:$4.88万
-
财政年份:2005
-
负责人:LAURA ROZEK
-
依托单位:
Methylation patterns in colorectal cancer
-
批准号:6937860
-
项目类别:
-
资助金额:$4.4万
-
财政年份:2005
-
负责人:LAURA ROZEK
-
依托单位:
海外基金